[Allogeneic hematopoietic stem cell transplantations for relapsed and refractory acute lymphoblastic leukemia following inotuzumab ozogamicin treatment].

Abstract

Inotuzumab ozogamicin (InO) was administered in three cases of relapsed/refractory adult acute lymphoblastic leukemia (ALL) before allogeneic hematopoietic stem cell transplantation (allo-SCT). One case developed extremely severe sinusoidal obstruction syndrome (SOS) but recovered after receiving defibrotide therapy. A gap of 63 days in the SOS case was noted from the last administration of InO to allo-SCT, the duration was 133 and 86 days for the other two cases, and the remaining risk factors for SOS were comparable in the three cases. In contrast to gemtuzumab ozogamicin (GO), the interval between InO exposure and allo-SCT has not been reported as a risk for SOS. Nevertheless, this case suggests that the intervals should be as long as possible.

• Authors: Satoshi Morishige, Yoshitaka Yamasaki, Shuki Oya, Takayuki Nakamura, Maki Yamaguchi, Kazutoshi Aoyama, Fumihiko Mouri, Yasuko Mizushima, Osamu Nakashima, Koji Nagafuji
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 63 Issue 4 Pg. 271-276 ( 2022) ISSN: 0485-1439 [Print] Japan
• PMID: 35491216 (Publication Type: Journal Article)

Chemical References

• Inotuzumab Ozogamicin

Topics

• Adult
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Hepatic Veno-Occlusive Disease (chemically induced)
• Humans
• Inotuzumab Ozogamicin (adverse effects)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (complications, drug therapy)
• Recurrence
• Remission Induction